
Loading, please wait...

Loading, please wait...

This double-blind, placebo-controlled trial at a tertiary referral centre evaluated intravenous immunoglobulin (IVIG) added to high-dose prednisone in adults with newly diagnosed idiopathic inflammatory myopathies. Forty-four patients were randomized to IVIG 2 g/kg or placebo at weeks 0, 4 and 8, with all patients receiving prednisone 1 mg/kg/day; 42 reached the primary endpoint (23 IVIG, 19 placebo). At week 12, the Total Improvement Score was higher with IVIG than placebo (60.0 vs 42.5; P=0.01). Moderate improvement was achieved by 91% versus 53% (P=0.01), and major improvement (post hoc) by 70% versus 26% (P=0.005). Median time to moderate response was 4 weeks with IVIG versus 12 weeks with placebo (P=0.005). One asymptomatic deep vein thrombosis occurred in the IVIG group. The small single-centre design and the post hoc nature of some outcomes mean the findings warrant confirmation in larger trials.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


This double-blind, placebo-controlled trial at a tertiary referral centre evaluated intravenous immunoglobulin (IVIG) added to high-dose prednisone in adults with newly diagnosed idiopathic inflammatory myopathies. Forty-four patients were randomized to IVIG 2 g/kg or placebo at weeks 0, 4 and 8, with all patients receiving prednisone 1 mg/kg/day; 42 reached the primary endpoint (23 IVIG, 19 placebo). At week 12, the Total Improvement Score was higher with IVIG than placebo (60.0 vs 42.5; P=0.01). Moderate improvement was achieved by 91% versus 53% (P=0.01), and major improvement (post hoc) by 70% versus 26% (P=0.005). Median time to moderate response was 4 weeks with IVIG versus 12 weeks with placebo (P=0.005). One asymptomatic deep vein thrombosis occurred in the IVIG group. The small single-centre design and the post hoc nature of some outcomes mean the findings warrant confirmation in larger trials.
Today

A randomized crossover trial evaluated fifth-year medical students interacting with an AI standardized patient versus a human standardized patient. The study revealed key differences in Mini-CEX scores, active engagement, and interview dynamics.
Today

A comparative evaluation of INNO-LiPA, Cobas 4800, and Amplicor highlights significant assay-dependent variation in high-risk HPV detection, emphasizing the clinical distinction between analytical sensitivity and screening specificity.
Today

A Canadian nutrition study reveals that higher diet costs predict lower dietary energy density and higher fruit intake, but also increase sodium and processed meat consumption.
Today

Idiopathic spinal cord herniation is a rare pathology presenting with progressive thoracic myelopathy. Early MRI identification and meticulous microsurgical reduction with dual bolstered dural defect repair prevent irreversible neurological deterioration.
Today

A novel smartphone-assisted biosensor utilizing molecularly imprinted polymers and catalytic nanozymes offers antibody-free, enzyme-free urinary microalbumin testing, enabling rapid, low-cost point-of-care screening for early chronic kidney disease.
Today